Mainstream

DURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitis

DURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitis

Post ContentdrrxRead More

You might also be interested in reading Bitcoin Holds $28K as Stocks Buckle Under Interest Rate Concerns.

March 27, 2025
In Mainstream